A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
Trial details
- Registry ID
- NCT04710576
- Phase
- Phase 2
The FDA approved Axatilimab (Niktimvo) on 14 Aug 2024.
Drug identity checked against registry records
Also recorded as Niktimvo; SNDX-6352
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)NCT04710576 | Syndax Pharmaceuticals | Phase 2 | Recruiting | 2023-04-07Actual |
| MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)NCT06132256 | Syndax Pharmaceuticals | Phase 2 | Completed | 2026-08-27Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2024-08-14Day | Axatilimab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA761411", "applicant_as_listed_by_fda": "INCYTE CORP", "brand_names": ["NIKTIMVO"], "active_ingredients": ["axatilimab-csfr"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20240814", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |